Development Pipeline

HPX-001

Is the lead clinical product. Hepyx as part of the A-TANGO consortium performs Phase 2 clinical studies of an innovative therapeutic strategy that improves hepatocyte proliferation through granulocyte colony-stimulating factor (G-CSF) and reduces systemic inflammation by repurposing an antagonist of TLR4 (toll-like receptor 4).

HPX-002

Undisclosed.

HPX-003

Undisclosed.

HPX-004

Undisclosed.

For more information on undisclosed assets, please contact us directly at info@hepyx.com